Journal article icon

Journal article

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Abstract:

BACKGROUND: A major clinical feature in multiple myeloma is the development of osteolytic bone disease. The increase in bone destruction is due to uncontrolled osteoclastic bone resorption. Until recently the factors responsible for mediating the increase in osteoclast formation in myeloma have been unclear. However, recent studies have implicated a number of factors, including the ligand for receptor activator of NFkappaB (RANKL) and macrophage inflammatory protein-1alpha. The demonstration...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/cncr.11125

Authors


Journal:
Cancer
Volume:
97
Issue:
3 Suppl
Pages:
818-824
Publication date:
2003-02-01
DOI:
EISSN:
1097-0142
ISSN:
0008-543X
Source identifiers:
112821
Language:
English
Keywords:
Pubs id:
pubs:112821
UUID:
uuid:88dc92ae-ae43-41ca-9218-33bc2cd4b2b2
Local pid:
pubs:112821
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP